Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Over a 35-year journey with a rare kidney disease, Ginger Murphy has become an advocate for her own health and welcomes the ...

After four years of heartbreak and a promise to his sister, Junction’s Aidan Cardwell looked to the sky—then finally stood ...

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy. Otsuka is hoping to file for approval of its ...

People need healthcare products and services regardless of what's happening with the economy. Which healthcare stocks could ...

Travere Therapeutics stock did suffer a bit of setback last week as the FDA moved back the anticipated decision date on a ...

Moderator Sagar Nigwekar, MD, of Massachusetts General Hospital in Boston, is joined by Edgar Lerma, MD, of the University of ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with ...

They trim our hair, polish our nails and ease our tired muscles - but beauticians, manicurists, hairdressers and barbers can ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today ...